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ABSTRACT
Primary plasma cell leukemia (pPCL) is a rare and aggressive form of plasma 
cell dyscrasia and may represent a valid model for high-risk multiple myeloma (MM). 
To provide novel information concerning the mutational profile of this disease, we 
performed the whole-exome sequencing of a prospective series of 12 pPCL cases 
included in a Phase II multicenter clinical trial and previously characterized at clinical 
and molecular levels. We identified 1, 928 coding somatic non-silent variants on 1, 
643 genes, with a mean of 166 variants per sample, and only few variants and genes 
recurrent in two or more samples. An excess of C > T transitions and the presence of 
two main mutational signatures (related to APOBEC over-activity and aging) occurring 
in different translocation groups were observed. We identified 14 candidate cancer 
driver genes, mainly involved in cell-matrix adhesion, cell cycle, genome stability, RNA 
metabolism and protein folding. Furthermore, integration of mutation data with copy 
number alteration profiles evidenced biallelically disrupted genes with potential tumor 
suppressor functions. Globally, cadherin/Wnt signaling, extracellular matrix and cell 
cycle checkpoint resulted the most affected functional pathways. Sequencing results 
were finally combined with gene expression data to better elucidate the biological 
relevance of mutated genes. This study represents the first whole-exome sequencing 
screen of pPCL and evidenced a remarkable genetic heterogeneity of mutational 
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patterns. This may provide a contribution to the comprehension of the pathogenetic 
mechanisms associated with this aggressive form of PC dyscrasia and potentially 
with high-risk MM.
INTRODUCTION
Plasma cell leukemia (PCL) is a highly aggressive 
form of plasma cell (PC) dyscrasia defined by the presence 
of more than 20% of circulating PCs in peripheral blood 
and/or an absolute circulating PC count greater than 
2 × 109/l [1]. PCL can be classified as either primary 
(pPCL), originating de novo at diagnosis, or secondary 
(sPCL), as a progression from a previous multiple myeloma 
(MM). PCLs occur rarely, being observed in approximately 
2–4% of PC dyscrasias, with pPCL accounting for 
approximately 50–70% of all cases [2–4]. PCL prognosis 
is very poor, with a median survival of 7–13 months for 
pPCL, and even worse for sPCL (2–7 months) [4, 5]. The 
pathogenetic mechanisms involved in either the primary or 
secondary forms remain to be fully elucidated [1, 4, 5].
As demonstrated by us and others, PCL shows more 
complex and heterogeneous molecular patterns than MM, 
with a greater number of associated genomic aberrations 
and, in particular, a higher incidence of 13q and 17p 
deletions and translocations involving immunoglobulin 
heavy chain locus, whereas very few patients with 
hyperdiploidy have been described [3, 6–10]. Overall, 
these findings also suggest that pPCL may represent 
a valid model for genetic and molecular alterations 
associated with high-risk MM.
Recently, we provided an extensive biological 
and molecular characterization of a panel of 23 pPCLs 
included in a Phase II prospective trial, aiming to evaluate 
the efficacy of novel biological drugs in the treatment of 
this aggressive form [11]. In particular, our data based on 
FISH and SNP array techniques showed the presence of 
IgH translocations in 87% of pPCL cases, with prevalence 
of t(11;14) and t(14;16), the occurrence of chr 13 deletion 
in 74% and of TP53 deletion/mutations in approximately 
40% of cases, and a low frequency of BRAF and RAS 
gene mutations [10]. Furthermore, microarray expression 
profiling revealed the presence of specific transcriptional 
signatures compared to MM, identifying genes and 
miRNAs potentially associated with clinical outcome in 
pPCL [12, 13].
Recently, next-generation sequencing (NGS) 
studies of MM enlarged the knowledge about the genetic 
landscape of this disease. Indeed, they collectively 
provided remarkable information concerning gene 
mutation signatures as well as the clonal and subclonal 
heterogeneous structure at diagnosis and its evolution 
during disease progression [14–17]. However, to the 
best of our knowledge, no NGS data are currently 
available in representative series of PCL. Here, we took 
advantage of our prospective series to decipher, by means 
of whole-exome sequencing (WES), the pattern of coding 
somatic mutations in pPCL. Sequencing results were 
combined with copy number and gene expression data 
to achieve a comprehensive and integrated view of the 
molecular landscape of pPCL.
RESULTS
Identification of coding somatic 
variants in pPCL
WES of 12 highly purified PC samples, together 
with five matched normal controls, was performed by 
Illumina technology. A mean of 95 M raw reads was 
generated per sample, of which 98% uniquely mapped 
to the GRCh37 reference genome. Referring to captured 
regions (62 Mb), we achieved a target coverage of 97% 
and a mean depth of 42.3x for both tumor and control 
cases (Suppl Table S1).
Since matched controls were not available in all 
pPCL cases, traditional somatic callers such as Mutect 
could not be used in our study. Therefore, to analyze all 
the 12 samples using the same method, we implemented a 
custom pipeline based on GATK caller using at first public 
databases and then the pool of control samples to filter out 
germline variants. Following this approach, we initially 
identified more than 52, 000 raw variants per tumor 
sample, including both single nucleotide variants (SNVs) 
and insertions/deletions (indels) (Suppl Table S2). Since 
our primary interest was in coding regions and splice sites, 
we applied a series of stringent filters to select coding 
non-silent variants, including non-synonymous (non-syn) 
SNVs and indels. First of all, after evaluation of target 
coverage in relation to sequencing depth, we chose to set 
at 10x the threshold to reduce the false positive rate. At 
this depth, all samples (both tumor and control cases) had 
at least 85% of covered target (Suppl Figure S1). Then, we 
removed all positions mapping out of coding regions and 
all variants already annotated in public databases, unless 
the same variant was also included in COSMIC or NCBI 
ClinVar catalogues (see Materials and Methods). Thus, 
we obtained a mean of 1, 525 coding non-syn SNVs and 
130 coding indels per tumor sample (Suppl Table S2). The 
CD138-negative bone marrow populations, available for 
five patients, were used at this step to filter out germline 
background, thus obtaining a mean of 149 and 9 coding 
somatic non-syn SNVs and indels per sample, respectively 
(Table 1). Lastly, we addressed specific analyses to the 
identification of somatic sub-clonal variants in the five 
tumor/normal pairs, and we found 93 sub-clonal non-syn 
SNVs and 1 sub-clonal insertion in 94 genes (Table 1). 
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All but one (in TCHH gene) were private variants 
occurring in individual cases (details in Suppl File S1). 
Full description of bioinformatics pipeline is provided in 
Supplementary Methods.
Globally, we identified a total of 1, 928 coding 
somatic non-silent variants (mean 166 per sample), 
including 1, 831 non-syn SNVs (missense and nonsense), 
90 indels and 7 splice site variants, distributed on 1, 643 
protein-coding genes (Figure 1A). All variants are provided 
with full annotation in Supplementary File S1 and 
summarized by gene in Supplementary File S2. Eighty-
one variants were validated by independent sequencing 
experiments, with a confirmation rate of 95%, in line with 
other cancer genome sequencing studies (Suppl File S3).
Concerning nucleotide changes, we observed an 
excess of C > T transitions, in agreement with what 
recently reported in MM [16] (Figure 1B). Furthermore, 
when looking at nucleotide context for coding 
somatic mutations in the whole dataset, we observed 
the occurrence of two main mutational signatures 
(Figure 1C). The first signature (corresponding to 
Signature 1A, according to the current classification 
[18]) was dominated by C > T transitions at NpCpG sites 
resulting from the spontaneous deamination of 5-methyl 
cytosine associated with aging. The second signature 
(Signature 2) was characterized by the prevalence of C > T 
and C > G in a TpCpN context, resulting from the over-
activity of APOBEC cytidine deaminase enzymes [18]. 
Both signatures were recently described in MM [16] 
as well as in other cancer types [18]. Evaluating the 
contribution of each nucleotide context in individual 
pPCL samples, few cases appeared driven by one 
single mutational signature, while the majority showed 
an admixture of the two processes (Suppl Figure S2). 
In line with recently published data, this seems to be 
a common feature in cancer genomes, regardless of 
tumor type [18]. Interestingly, when considering the 
translocation groups of our dataset, three out of the four 
samples carrying the t(14;16) translocation involving 
MAF gene showed a distinct APOBEC mutational 
signature, while among the other five samples carrying 
t(11;14) or t(4;14), one case presented a distinct age-
related signature and three other samples showed 
an admixture of both Signatures 1A and 2, with the 
predominant contribution of age-related process. Thus, 
in agreement with what recently presented for MM 
by Walker et al. [19], we can confirm also for pPCL 
(although in a relatively small dataset) that t(14;16) 
cases predominantly had an APOBEC signature.
Integration with copy number alterations
Somatic copy number alterations (CNAs) in 
the 12 pPCLs were identified from WES data using 
EXCAVATOR software. Globally, we found a mean of 
20 CNA traits per sample, with more frequent deletions 
than amplifications (Figure 2; Suppl File S4). The CNAs 
here identified were concordant to those previously 
characterized in the same samples by using Affymetrix 
SNP Array [10] and in agreement with the known PCL 
genomic signature, including deletions of chrs 1p, 8p, 13q 
and 17p, and gain of chr 1q. To evaluate the global amount 
Table 1: Coding somatic non-silent variants identified in pPCL panel
Sample
Somatic Somatic sub-clonal Total No. 
Non-syn 
SNVs
Total No. 
Indels
Total No. 
Somatic 
Variants
Non-syn 
SNVs
Indels Non-syn 
SNVs
Indels
PCL-016 148 4 17 0 165 4 169
PCL-017 160 11 0 0 160 11 171
PCL-018 25 2 9 1 34 3 37
PCL-019 133 5 17 0 150 5 155
PCL-020 195 15 0 0 195 15 210
PCL-026 232 6 34 0 266 6 272
PCL-027 156 16 0 0 156 16 172
PCL-030 179 11 0 0 179 11 190
PCL-032 176 8 0 0 176 8 184
PCL-035 203 14 0 0 203 14 217
PCL-036 146 16 0 0 146 16 162
PCL-038 40 2 17 0 57 2 59
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of somatic alterations carried by each of the 12 pPCLs, 
coding somatic variants (non-syn SNVs and indels) and 
CNA results were summed up by sample (Figure 3). 
PCL-026 and PCL-020 resulted the most impacted 
samples, with the highest number of variants and CNAs, 
respectively.
Lastly, in order to assess CN state of the 1, 643 
mutated genes, WES and CNA results were integrated 
for all the 12 pPCLs (Suppl File S5). We identified 
three homozygous deletions involving three genes, 
namely BIRC2 on chr 11 and TRPM6 on chr 9 (both in 
PCL-019) and TRAF3 on chr 14 (in PCL-017). 
Furthermore, we found 77 genes concomitantly affected 
by mutation and 1-copy loss, suggesting a potential 
tumor suppressor gene (TSG) function (Suppl File 
S5). Among them, TP53 resulted the most recurrently 
disrupted gene (three missense variants and one 
frameshift indel in four cases, all associated with deletion 
of the other allele (see below for further details)), while 
BIRC2 and TRAF3, besides the homozygous deletions 
above described, were found biallelically affected in two 
additional cases, presenting respectively a truncating 
mutation and a frameshift deletion, both associated with 
loss of the remaining allele.
Candidate driver genes in pPCL
Using DOTS-Finder tool and taking into account 
gene mutation rates calculated in our samples with 
respect to COSMIC and TCGA databases, we identified 
14 statistically significant recurrently affected genes with 
potential driver role in pPCL. Among them, we found 
genes involved in cell-matrix adhesion and membrane 
organization (SPTB, CELA1), cell cycle and apoptosis 
(CIDEC), genome stability (KIF2B), RNA binding and 
degradation (DIS3, RPL17), and protein folding (CMYA5) 
(Table 2). In particular, DIS3, coding for an RNA 
exonuclease catalytic subunit of the exosome complex 
and described as one of the most recurrently mutated 
genes in MM [14, 17, 20], resulted affected in three PCLs 
(25%). In two samples the mutation involved the same 
aminoacid position but introducing two different changes 
(R780K and R780T), both already reported in literature 
for MM [17, 20]; in the third case, the mutation was in 
Figure 1: Coding somatic variants identified in the 12 pPCL samples. A. Distribution of coding somatic non-silent variants 
according to amino acid changes or reading frameshifts. B. Classification of coding somatic SNVs (both syn and non-syn) by nucleotide 
change. Transitions are in green (C > T, T > C) and transversions are in blue (C > A, C > G, T > A, T > G). C. Mutational signatures in 
pPCL. Coding somatic SNVs identified in the 12 samples were classified according to nucleotide change and sequence context into the 
96 possible mutated trinucleotides (listed horizontally according to the conventional order). Substitutions are displayed in different colors 
along the horizontal axis and number of mutations attributed to each type is shown on the vertical axis.
Oncotarget17547www.impactjournals.com/oncotarget
homozygous state, associated with deletion of the other 
allele. In addition, the gene showed hemizygous deletion 
in other seven pPCLs. Although deserving investigations 
in larger collections to assess their actual recurrence, 
these genes might represent novel potential markers for 
translational clinical applications.
Pathways affected by somatic mutations in pPCL
After removal of potentially spurious genes 
frequently mutated in cancer but not necessarily relevant 
to tumor biology [21], functional enrichment analysis 
of the mutated genes using ToppGene evidenced five 
significantly enriched pathways, including cadherin and 
Wnt signaling, extracellular matrix (ECM)-receptor 
interaction, ECM organization, and G2/M cell cycle 
checkpoint (Table 3).
In cadherin/Wnt signaling pathways, we globally 
recognized 51 genes, 30 of which (59%) showed a 
cadherin domain. Among cadherin genes, the most 
recurrent ones were PCDH15 (four cases), DCHS1 
and FAT3 (each in three samples). Ten pPCLs showed 
mutations in two or more cadherin genes. Furthermore, 
cadherin genes were principally identified in the 
Figure 2: Copy number analysis. Copy number alterations were identified starting from WES data by using EXCAVATOR software. 
The Circos plot represents somatic amplifications (red) and deletions (green) found in each case, distributed across all chromosomes. 
Samples are displayed according to increasing case number from outer to inner track. Colors of track borders indicate translocation groups: 
t(14;16) in red, t(11;14) in blue, t(14;20) in green, t(4;14) in orange. PCL-020 resulted as outlier with the greatest number of CNAs and a 
basal tetraploidy with regions till to five copies.
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protocadherin (PCDH) family (19/30, 63%). Most 
PCDH mutated genes (15/19, 79%) belonged to the 
three tandem 5q31 region gene clusters [22].
Notably, 49 genes were involved in ECM-
receptor interaction and organization pathways, 34 of 
which (69%) annotated as proteinaceous ECM cellular 
components, including collagen and laminin genes, 
ADAM metallopeptidases and members of the aggrecan/
versican proteoglycan family. Ten PCLs resulted affected 
in these ECM cellular components, and six cases presented 
mutations in five genes or more.
Finally, 10 genes were involved in G2/M cell cycle 
checkpoint pathway in nine PCLs. Among them, TP53 and 
ATM (four cases) were the most recurrent ones, followed 
by ATR and CDKN1A (three cases) and BRCA1 (two 
cases). Notably, six PCL cases showed the involvement 
of the kinase ATM (PCL-017, PCL-026, PCL-030) or ATR 
(PCL-019, PCL-035) in a mutually exclusive fashion, or 
in a combined manner (PCL-020). Additionally, TP53 
gene was frequently found altered in association with at 
least one another gene of this pathway: ATM (PCL-017), 
CDKN1A and RPS6KA1 (PCL-027), or both ATM and 
CDKN1A, together with CDC25A, CHEK2 and PRKDC 
genes, in the most affected case (PCL-030). No concurrent 
mutations in ATR and TP53 were evidenced.
Furthermore, we identified other eight affected 
pathways that, although did not reach statistical 
significance after p-value correction, are noteworthy since 
notoriously involved in MM and lymphoid malignancies 
[23, 24] and targeted by current molecular therapies [25]. 
They included the proteasome and ubiquitin-mediated 
proteolysis machineries and the TNF, NF-kB, PI3k-Akt, 
MAPK and Hippo signaling pathways (Suppl Table S3).
Interestingly, if looking at impact prediction of 
variants affecting all these pathways, we observed 
a statistically significant enrichment for damaging 
variants (P < 0.01, Fisher exact test) (Suppl Figure S3A). 
The probability of having the same fraction of damaging 
variants randomly sampling the same number of 
mutations in our dataset was estimated to be 10−5 and 
10−4 for the five enriched and the eight selected pathways, 
respectively (Suppl Figure S3B-S3C). Moreover, 
when tested individually, Wnt signaling and G2/M cell 
cycle checkpoint (q-value < 0.05) and MAPK pathway 
(q-value < 0.01) maintained a significant enrichment for 
damaging variants with respect to background.
Comparison with multiple myeloma 
recurrent genes
We evaluated in our series the occurrence of somatic 
variants in 11 genes recurrently mutated in MM [17]. 
Globally, seven genes were affected in our samples 
(TP53, DIS3, BRAF, KRAS, NRAS, FAM46C, TRAF3), 
Figure 3: Global amount of somatic alterations per sample. The numbers of coding somatic non-silent variants (non-synonymous 
SNVs and indels) and CNA regions (gains and losses) were summed up by sample, to have an overview of the global burden of somatic 
alterations carried by each case.
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while ACTG1, CYLD, PRDM1 and RB1 carried no 
variant (Suppl Table S4). TP53 was the most frequent, 
completely inactivated in four pPCLs (33%) as above 
mentioned. Three pPCLs (25%) carried variants in DIS3, 
in addition to other seven samples showing hemizygous 
deletion, and this gene resulted a statistically significant 
driver gene in our dataset. The remaining five genes 
showed individual missense and frameshift variants. 
Table 2: Statistically significant recurrently affected genes with potential driver role in pPCL
Gene Gene Name
No. Cases 
(%)
No. 
Variants
No. Non-syn 
SNVs
No. 
Indels
q-value Function
HLA-DQA1
major 
histocompatibility 
complex, class II, 
DQ alpha 1
3 (25%) 3 - 3* 3.89E-09 immune response
CIDEC
cell death-inducing 
DFFA-like effector c
3 (25%) 1 1* - 3.07E-05 apoptosis
CELA1
chymotrypsin-like 
elastase family, 
member 1
3 (25%) 1 - 1 7.42E-05
proteolysis, 
cell membrane 
and matrix 
organization
SRRM5
serine/arginine 
repetitive matrix 5
3 (25%) 2 2* - 7.89E-05 unknown
CCDC144NL
coiled-coil 
domain containing 
144 family, 
N-terminal like
3 (25%) 2 - 2 8.59E-05 unknown
SPTB
spectrin, beta, 
erythrocytic
3 (25%) 5 5 - 0.00280
cell membrane 
organization and 
stability
DIS3
exosome catalytic 
subunit DIS3
3 (25%) 3 3 - 0.00427
RNA binding, 
RNA degradation
FAM166B
family with 
sequence similarity 
166, member B
2 (16%) 1 - 1* 0.01062 unknown
RPL17
ribosomal 
protein L17
2 (16%) 2 1 1 0.01405
RNA binding, 
translation
CMYA5
cardiomyopathy 
associated 5
1 (8%) 7 7 - 0.02032 protein binding
UNC80 unc-80 homolog 4 (33%) 4 4 - 0.02762
ion transmembrane 
transport
SCN9A
sodium channel, 
voltage-gated, type 
IX, alpha subunit
3 (25%) 3 3 - 0.03008
ion transmembrane 
transport
ZNF598
zinc finger 
protein 598
3 (25%) 1 - 1* 0.03008
translation 
repressor
KIF2B
kinesin family 
member 2B
2 (16%) 2 1 1 0.09976
chromosome 
segregation, 
genome stability
Note: *Identical recurrent variants found in unpaired pPCL samples annotated in both dbSNP and COSMIC catalogue and confirmed 
somatic in COSMIC website.
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Table 3: Pathways significantly enriched in mutated genes by ToppGene analysis
Pathway Source p-value FDR q-value No. Damaging/ 
Total variants
Genes
Cadherin 
signaling 
pathway
PantherDB 
(ID P00012)
1.26E-07 3.07E-04 24/48
PCDH15*, FZD6, PCDH7*, PCDH20*, 
CDH20*, DCHS1*, CDH17*, CDH4*, 
CDH9*, CDH23*, CTNNA2, PCDHGB1*, 
PCDHGC5*, PCDHGC4*, PCDHGA2*, 
PCDHGA1*, PCDHA7*, PCDHA13*, 
PCDHAC1*, PCDHB2*, PCDHB3*, 
PCDHB7*, PCDHB8*, PCDHA2*, 
PCDHA1*, PCDHA3*, CELSR3*, FAT1*, 
FAT2*, FER, FZD10, CDHR2*, FAT3*, 
YES1, PCDH11X*
ECM-
receptor 
interaction
BioSystems: 
KEGG 
(ID 83068)
2.01E-06 2.45E-03 9/26
CD36, SV2B, COL1A2†, COL1A1†, 
COL5A1†, COL6A3†, COL4A2†, DAG1†, 
COL6A6†, RELN†, TNN†, FN1†, THBS3, 
TNXB†, HMMR, HSPG2†, ITGA1, LAMB1†, 
LAMA4†, LAMA5†, LAMA2†, LAMA3†
Cell Cycle 
G2/M 
Checkpoint
MSigDB C2: 
BioCarta 
(ID M8560)
1.25E-05 1.02E-02 13/20‡
ATM, ATR, BRCA1, CDC25A, CDKN1A, 
PRKDC, EP300, CHEK2, RPS6KA1, TP53
Wnt 
signaling 
pathway
PantherDB 
(ID P00057)
2.17E-05 1.18E-02 36/66‡
MYH13, PCDH15*, FZD6, PCDH7*, 
MYH7, PCDH20*, CDH20*, DCHS1*, 
CDH17*, CDH4*, CDH9*, CDH23*, 
PRKCZ, PPP2R5E, PPP3R2, CREBBP, 
CTNNA2, PLCB4, PCDHGB1*, PCDHGC5*, 
PCDHGC4*, PCDHGA2*, PCDHGA1*, 
DVL3, PCDHA7*, PCDHA13*, PCDHAC1*, 
PCDHB2*, PCDHB3*, PCDHB7*, 
PCDHB8*, PCDHA2*, PCDHA1*, 
PCDHA3*, EP300, CELSR3*, FAT1*, FAT2*, 
SRCAP, FZD10, INO80, TP53, CDHR2*, 
FAT3*, PCDH11X*, KREMEN1, ITPR2, 
MYH14, PLCB1
Extracellular 
matrix 
organization
BioSystems: 
REACTOME 
(ID 576262)
2.50E-05 1.18E-02 22/51
ACTN1, ACAN†, COL6A5†, DDR2, 
LTBP4†, ADAMTS9†, COL1A2†, COL1A1†, 
COL15A1†, COL17A1†, COL9A3†, PDGFB, 
COL9A1†, COL5A1†, COL6A3†, COL4A2†, 
PLEC, VCAN†, DAG1†, ADAMTS16†, 
ADAMTS18†, COL6A6†, BCAN†, PSEN1, 
DSPP†, TNN†, PTPRS, FBN2†, FGA, FN1†, 
ADAMTS5†, TNXB†, ADAM18, LEPREL1†, 
HSPG2†, ICAM4, ITGA1, LOXL4, LAMB1†, 
LAMA4†, LAMA5†, LAMA2†, LAMA3†, 
FBN3†
Note: *30 genes showing a cadherin domain according to significant enrichment by ToppGene analysis (InterPro IPR002126 domain, 
q-value 3.24E-08, FDR correction). †34 genes annotated as proteinaceous extracellular matrix (ECM) cellular components according to 
significant enrichment by ToppGene analysis (GO Cellular Component GO:0005578, q-value 4.62E-04, FDR correction). ‡Significant 
enrichment for damaging variants (q-value < 0.05, Bonferroni correction).
BRAF carried two missense mutations in the same 
sample, both already described in MM. FAM46C 
presented a novel variant, never previously reported 
for other tumors, besides being deleted in other five 
PCLs. KRAS and NRAS resulted affected in two distinct 
samples and both mutations were already described 
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for MM; moreover, NRAS resulted deleted in five 
PCLs, while amplified only in the sample harboring the 
mutation. Finally, TRAF3 was completely inactivated 
in two samples, as aforementioned. All variants were 
confirmed by Sanger sequencing (Suppl File S3). 
Overall, we observed that KRAS and NRAS were three-
fold less frequent, while DIS3 and TP53 were till to two-
fold more recurrent in pPCL than MM considered as a 
whole [16, 17, 20] (Figure 4).
Gene expression profiles of mutated genes in 
MMs and pPCLs
A proprietary dataset of 55 MM and 21 pPCL 
cases (comprising the 12 in this study) and four bone 
marrow healthy donors profiled on Affymetrix Gene 
1.0 array [12] was exploited to assess the expression 
profiles of the mutated genes (1, 598 of which included 
in the chip array). A hierarchical clustering based 
on the 132 mutated genes found among the most 
variably expressed genes (2AVEFC) of our dataset 
revealed that sample grouping was principally driven 
by the main cytogenetic translocations (Figure 5). 
Specifically, we found a good separation of the two 
t(4;14) (TC4) and t(14;16)/t(14;20) (TC5) MM-
PCL sample groups (15/15 and 14/14, respectively; 
P < 10−4), whereas t(11;14) cases (TC1) were divided 
in two sub-branches, clearly separating MM from 
PCL samples (11/12 MMs and 7/8 PCLs; P < 10−4). 
Additionally, three distinct clusters were identified for 
TC2 (12/13; P < 3 × 10−4) and TC3 MM cases (7/12; 
P < 10−4, and 4/12; P < 9.4 × 10−3). Notably, functional 
enrichment in regulation of cellular developmental 
process and morphogenesis, phosphatase activity, 
ECM/cytoskeleton organization, cell adhesion and 
endocytosis processes was observed in these 132 genes 
(Suppl Table S5). Interestingly, the probability 
of replicating the same sample clustering using a 
comparable number of genes randomly extracted from 
the whole 2AVEFC list (regardless of mutational state) 
was calculated as P < 0.004. This finding indicated that 
these 132 genes, representing the 11% of the 2AVEFC 
list, had peculiar clustering abilities and strongly 
suggested that genes found mutated in pPCL may also 
have relevant biological roles in the context of the 
different molecular and clinical types of MM.
Finally, a two-class supervised analysis comparing 
pPCL to MM samples on the 1, 598 mutated genes 
identified 102 differentially expressed genes (DEGs), 
of which 42 up- and 60 down-regulated in pPCL 
versus MM group (Suppl Table S6). Specifically, 
up-regulated genes were functionally enriched in 
regulation of transcriptional processes, while several 
down-regulated genes were involved in cell death 
regulation. Interestingly, concerning genes included in 
the five enriched functional pathways aforementioned, 
we found ATM and CHEK2 (G2/M cell cycle 
checkpoint) as well as CD36, HMMR and RELN (ECM-
receptor interaction pathway) as down-regulated in 
pPCL versus MM, whereas EP300 (Wnt signaling 
pathway) resulted up-regulated in pPCL as compared 
to MM samples. Notably, 33 out of the 102 mutated 
Figure 4: Recurrence of the 11 multiple myeloma genes in our pPCL series with respect to MM published 
datasets. Recently published datasets for multiple myeloma include: Walker et al., Blood 2012 (22 cases, [20]), Lohr et al., Cancer Cell 
2014 (203 cases, [17]) and Bolli et al., Nat. Commun. 2014 (67 cases, [16]). Recurrence rates were calculated as the percentage of positive 
samples on the total number of cases included in each study.
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DEGs (32%) were in common with our published 
503-gene transcriptional signature distinguishing pPCL 
and MM [12].
DISCUSSION
Over the last few years, NGS technology has 
extended our knowledge of the genetic alterations associated 
with transformation and progression in MM. Notably, 
these studies showed a considerable number of somatic 
variants per patient, few recurrently mutated genes with 
pathogenetic significance, and an heterogeneous sub-clonal 
structure at presentation [16, 17, 20, 26]. Furthermore, 
although performed on only two PCL cases, Walker et 
al. [15] recently demonstrated that number and pattern of 
somatic variants at PCL stage are higher and more complex 
than in MM, smoldering multiple myeloma (SMM) and 
monoclonal gammopathy of undetermined significance 
(MGUS). In the present study, we aimed to provide novel 
and more comprehensive information concerning the 
mutational profile of pPCL by performing WES of highly 
purified malignant PCs from a prospective panel of pPCL 
patients already extensively characterized at clinical and 
molecular levels in our previousreports [10–13].
Figure 5: Hierarchical clustering of the 55 MM-21pPCL-4N dataset based on the expression levels of the 132 most 
variable and mutated genes. Data were previously generated on GeneChip Human Gene 1.0 ST array platform [12]. Samples were 
labelled according to tumor type (MM, multiple myeloma; p, primary plasma cell leukemia), translocation/cyclin D (TC) classification and 
the main associated cytogenetic alterations. Significant sample clusters, according to major IgH translocations, are highlighted.
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Our WES analysis in pPCL confirmed and extended 
the remarkable genetic heterogeneity associated with MM. 
Based on our results, 1, 928 coding somatic non-silent 
variants distributed on 1, 643 genes were identified in the 
whole dataset, with a mean of 166 variants per sample. 
However, as already observed for MM, the recurrence 
of identical variants did not appear a frequent event 
in pPCL, where only 1.9% of variants were recurrent 
in two or more samples, even if affecting genes with 
pathogenetic relevance already reported in COSMIC and 
MM [14]. Though we could have slightly over-estimated 
the number of identified variants due to the availability of 
paired samples only in five patients, our study represents 
so far the most comprehensive overview of the mutational 
patterns of primary PCL.
In our study on pPCL, we observed that, among 
those genes found recurrently mutated in MM, KRAS and 
NRAS were three-fold less frequent, while DIS3 and TP53 
were till to two-fold more recurrent in pPCL than MM 
considered as a whole [16, 17, 20]. These differences in 
mutational frequencies could be partially explained by the 
composition of our pPCL series in terms of cytogenetic 
abnormalities, not strictly comparable to that generally 
observed for MM. This mainly concerns TP53 and DIS3, 
whose mutations have been reported in several MM series 
as preferentially associated, respectively, with chr 17p 
deletion [16, 27] and non-hyperdiploid status [17]. Both 
these conditions are over-represented in our pPCL dataset, 
in line with previous reports in other pPCL series [3, 9, 28]. 
In particular, as regards TP53 mutations, it should be 
noted, as aforementioned, that all the four TP53-mutated 
cases also carried del(17p), and the frequent co-occurrence 
of these two genetic alterations is compatible with the 
demonstrated association of TP53 inactivation with 
advanced forms of malignancy (also substantiated by its 
nearly ubiquity in MM cell lines) [29]. Three of the four 
TP53 mutations we found (I195T, R273C, P278L) were 
deleterious missense variants targeting the DNA binding 
domain and frequently reported as mutated (IARC TP53 
Database, http://p53.iarc.fr/), also in MM patients [16, 17]; 
the fourth variant was a deletion of ten nucleotides, of 
which eight at the 3′-end of intron 9 and two at the 5′-end 
of the following exon 10, introducing a reading frameshift 
and consequently a premature stop codon in the first part 
of the oligomerization domain (I332Pfs*4). As regards 
NRAS and KRAS, a slight enrichment of mutated cases 
among hyperdiploid MM patients can be observed in both 
the main WES studies for MM: both NRAS and KRAS 
were reported mutated in 18.5% of non-hyperdiploid 
(NHD) and 30% of hyperdiploid (HD) patients in the 
dataset from Bolli et al. [16], while in the cohort by Lohr et 
al. [17] NRAS mutations were detected in 16.3% of NHD 
and 22.4% of HD patients, and KRAS mutations in 18.6% 
of NHD and 26.7% of HD cases (although association 
did not reach statistical significance). Based on these 
data, the low occurrence of NRAS and KRAS mutations 
in our 12 pPCLs could be partly expected. Concerning 
DIS3, although its role in the pathogenesis of the disease 
remains to be elucidated, this gene was characterized as 
potential tumor suppressor in MM. This suggestion is 
based on the loss of enzymatic activity caused by the MM-
associated DIS3 mutations that have been functionally 
studied [30], and on the observation of frequent loss 
of heterozygosity involving DIS3 (also occurring in 
our dataset) due to the combination of gene mutation 
and chr 13 deletion. Anyhow, further investigations in 
considerably larger cohorts will be definitely useful to 
confirm the involvement of these genes in pPCL and their 
actual recurrence with respect to MM.
Interestingly, we identified significantly enriched 
pathways associated with mutated genes in pPCL, namely 
cadherin/Wnt signaling, ECM-receptor interaction and 
organization, and G2/M cell cycle checkpoint. Notably, 
both Wnt signaling and G2/M cell cycle checkpoint 
pathways resulted enriched also in damaging variants, 
thus enforcing the hypothesis of their crucial involvement 
in pPCL biology. Finally, several of the candidate driver 
genes found in our study were included or strictly 
correlated with these pathways.
Cadherins play a major role in cell-cell adhesion 
and tissue integrity and homeostasis maintenance and 
their alterations are associated with tumorigenesis and 
metastasis; in particular, several protocadherins were 
recognized as candidate TSGs, mainly silenced by 
methylation in different solid tumors [31]. Furthermore, 
cadherins are functionally associated with cytoplasmic 
members of the catenin family, including β-catenin 
which represents a crucial player in Wnt signaling [32]. 
Notably, two genes of the cadherin/Wnt cascade, 
PPP2R5E and EP300, resulted as potential drivers for 
pPCL (though with q-value slightly above significance 
threshold, probably due to the small size of our dataset). 
PPP2R5E, involved in apoptosis control, was proposed 
as TSG in acute myeloid leukemia [33]. EP300 encodes 
a histone acetyltransferase, whose altered transcriptional 
and epigenetic functions were associated to leukemia and 
other cancers [34]. Notably, EP300/β-catenin interaction 
is critical in Wnt pathway regulation and particularly in 
mediating neoplastic transformation [35]. Moreover, 
among the mutated cadherin genes interacting with Wnt 
pathway, FAT1 (FAT atypical cadherin 1) was found 
mutated in solid tumors [36] and chronic lymphocytic 
leukemia [37]. When inactivated, FAT1 is unable to 
sequester β-catenin at the cell membrane, which in turn 
promotes the activation of Wnt cascade and tumor growth 
[38]. Notably, other FAT genes frequently mutated in solid 
tumors [38] resulted affected in our series, such as FAT2 
(one case) and FAT3 (three cases), in a mutually exclusive 
fashion. Interestingly, FAT3 was found recurrently mutated 
in a recently published MM series [16].
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ECM is part of the bone marrow (BM) 
microenvironment and includes many components as 
fibronectin, laminins, collagens and proteoglycans. ECM 
can provide a protective environment against drug effects, 
thus favoring the emergence of chemoresistant cancer 
cells [39]; for instance, fibronectin was found directly 
involved in the mechanisms of cell adhesion-mediated 
drug resistance of MM cells [40], whereas collagen 
degradation in the BM ECM by matrix metalloproteinases 
may contribute to MM progression [41]. Recent evidences 
suggested that ECM components expressed by myeloma 
patients differ from those of healthy individuals, 
involving the progressive up-regulation of specific ECM 
proteins in the transition from MGUS to MM [42]. 
Here, we found several mutated ECM components, 
including proteoglycans and proteases, involved in ECM 
homeostasis and remodeling, as well as collagen and 
laminin genes, which can interact with surrounding cells 
through integrin membrane receptors and participate in 
differentiation, adhesion and migration [43]. Finally, 
enrichment in ECM organization and cell adhesion 
functions was found in the 132 most variably expressed 
among the mutated genes in our analyses, further 
supporting the hypothesis that they could play important 
pathogenetic roles in these PC disorders. Overall, 
based on these considerations, alterations of both these 
pathways may be strongly involved in the mechanisms of 
extramedullary spread associated with pPCL.
The G2/M cell cycle checkpoint pathway represents 
a complex process interconnected with several other 
cascades, first of all with the DNA damage response (DDR) 
mechanisms. MM and in particular PCL are disorders 
characterized by high genetic instability; the expression 
of genes involved in distinct DNA repair mechanisms has 
recently been associated with a disease-specific prognostic 
relevance in MM [44]. Here, we evidenced the marked 
involvement of TP53 gene. Although referring to a 
relatively small series, its occurrence was higher than that 
reported for MM in previous NGS studies [16, 17, 20]. The 
increased frequency of TP53 deletions found in our pPCLs 
with respect to MM is confirmed in all published pPCL 
series [3, 6, 7, 9, 28] and can be partially explained by the 
different composition in terms of cytogenetic alterations 
between pPCL and MM. Furthermore, we reported the 
recurrent involvement of ATM and ATR genes, which 
encode the two checkpoint kinases required for cell cycle 
arrest and DNA damage repair activation. In particular, 
the PI3/PI4-kinase ATR, carrying four missense variants in 
three pPCLs, resulted a potential driver gene in our series. 
Recently, ATR inhibitors showed to sensitize tumor cells 
to topoisomerase inhibitors already used in clinical trials, 
thus suggesting the possibility of a combined strategy to 
enhance cancer treatment efficacy [45]. The co-occurrence 
of mutations in different members of the DDR cascade 
downstream to ATM or ATR (CHEK2, CDC25A, TP53, 
CDKN1A, BRCA1) may suggest a potential synergic role 
in deregulated DNA repair function in pPCL. This is of 
particular relevance since our study involved patients 
that did not receive any previous treatment, suggesting 
that alterations of this function may represent a specific 
hallmark of tumorigenesis in pPCL.
Overall, our results suggested a peculiar 
involvement for a variegated set of genes and pathways 
in pPCL biology and evidenced the importance of their 
comprehensive characterization to extend the knowledge 
of molecular mechanisms responsible for this disease. 
Moreover, since pPCL is a highly aggressive form of 
PC dyscrasia, understanding its molecular processes 
might also shed new light and help to unravel the 
genetic complexity of high-risk MM. Candidate 
genes identified in these pathways might be useful as 
actionable targets for therapeutic approaches, thus 
opening new perspectives or improving the efficacy of 
already existing strategies.
MATERIALS AND METHODS
Patients and sample preparation
Pathological specimens were collected from 
12 untreated pPCL patients, all but one (PCL-038) 
included in a multicenter Italian clinical trial (RV-
PCL-PI-350, EudraCT N° 2008-003246-28), an open 
label, exploratory, single arm, two-stage study aimed at 
evaluating safety and anti-tumor activity of combined 
lenalidomide and dexamethasone as first-line treatment 
for previously untreated pPCLs [11]. All cases have been 
characterized by fluorescent in situ hybridization (FISH)
for the main MM genomic aberrations (Suppl Table S7) 
and profiled for whole-genome DNA copy number and 
gene and miRNA expression by microarray technology 
[10, 12, 13]. Data are available at NCBI GEO repository 
(Accession numbers GSE39383, GSE39925 and 
GSE37053).
Highly purified (≥ 90%) bone marrow PCs were 
obtained as previously reported [46]. CD138-negative 
bone marrow population (CD138+ < 0.5%, as assessed by 
FACS analysis) was obtained for five of the 12 patients 
and used as normal counterpart for WES.
Whole-exome capture and sequencing
Whole-exome capture for the 12 pPCLs and five 
control samples was performed using the TruSeq Exome 
Enrichment kit (62 Mb) (Illumina, San Diego, CA, USA). 
Libraries were sequenced on an Illumina GAIIx platform, 
in paired-end 85-cycle runs (see Supplementary Methods 
for details). Raw data have been deposited in NCBI 
Sequence Read Archive (SRA), under Study Accession 
Number SRP051153.
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WES data analysis
Since matched controls were not available in all 
pPCL cases, traditional somatic callers could not be used 
in our study. Therefore, to analyze all the 12 samples using 
the same method, we implemented a custom pipeline based 
on GATK UnifiedGenotyper caller and used at first public 
databases to filter out known polymorphisms and then 
the pool of control samples to further remove germline 
variants. Briefly, reads were mapped to the NCBI human 
reference genome (GRCh37) using BWA [47]. Variant 
calling for SNVs and indels was performed using GATK 
software [48], and functional annotation was carried out 
using Annovar [49], according to Ensembl GenCode v67 
gene model. By applying a stringent custom filtering 
pipeline, any variant already annotated as polymorphism 
in public databases (dbSNP, 1000 Genomes, ESP) was 
discarded, unless present also in COSMIC (v67) or NCBI 
ClinVar database given their potential relevance for tumor 
or clinical associations. Finally, control samples were 
used to remove germline background and to select coding 
somatic non-silent variants, including non-synonymous 
SNVs and indels. Full description of bioinformatics 
pipeline and filtering steps is provided in Supplementary 
Methods.
Confirmation of WES variants was performed 
by PCR amplification and Sanger or Roche Junior 
sequencing. Calculation of nucleotide contexts for 
identification of mutational signatures was performed 
according to Alexandrov et al. [50].
Since control samples were not available for 
all the investigated cases, there was the possibility 
that calls in unpaired samples still included private 
polymorphisms, not removed because absent in the 
control pool. To evaluate the possible carry-over of 
germline background, our pipeline was applied on the 
five paired pPCLs by analyzing them first in “paired” 
manner (subtracting to each tumor its matched control, 
as described in Supplementary Methods) and then in 
“unpaired” manner (subtracting to each tumor the pool 
of the other not matched controls). Results showed that 
the private background was ultimately marginal thanks 
to the adopted filtering steps (Suppl Table S8). Identical 
recurrent variants found in two or more samples and 
annotated in both dbSNP and COSMIC catalogue were 
manually checked in COSMIC website for somatic status. 
The few variants (all occurring in unpaired pPCLs) whose 
somatic status was not confirmed in COSMIC website 
were flagged for further analyses as they could be residual 
germline background (Suppl Table S9).
Copy number analysis and integration
Genome-wide analysis of somatic DNA copy 
number alterations (CNAs) was performed on WES data 
using the read count-based EXCAVATOR software [51], 
with default parameters and setting c = 1 (Supplementary 
Methods). To assess the CN state of mutated genes, genes 
mapping in CNA regions were retrieved using UCSC 
RefSeq transcript annotation track. In case of multiple 
transcripts for the same gene, the largest RefSeq transcript 
was chosen. Then, this CNA-gene list was intersected 
with WES mutated gene list, to evaluate the CN state of 
affected genes across the whole dataset.
Identification of driver genes
Specifically implemented for the analysis of small 
tumor datasets, DOTS-Finder tool [52] was applied with 
default settings to identify significant recurrently affected 
genes with potential driver role in our series, based on 
functional and frequentist approaches taking into account 
gene length, dataset size and number of non-synonymous/
synonymous variants found in our samples with respect to 
COSMIC and The Cancer Genome Atlas (TCGA) cancer 
databases. Identical recurrent variants found in unpaired 
pPCL samples and annotated in both dbSNP and COSMIC 
catalogue but not confirmed as somatic in COSMIC website 
were considered just once to not over-score corresponding 
genes. Annovar output was used to produce the initial marf 
file and a q-value < 0.1 (Benjamini-Hochberg correction) 
was set to define statistically significant driver genes.
Pathway analysis
Functional enrichment analysis of the mutated 
genes was performed using ToppGene Suite [53]. 
Pathways with q-value < 0.05 (FDR Benjamini-
Hochberg correction) were defined as significantly 
enriched. Before running ToppGene, a list of 
potentially spurious genes frequently found mutated 
in cancer but not necessarily relevant to tumor biology 
was compiled according to Lawrence et al. [21]. 
Twenty-three of them resulted as present in our list of 1, 
643 mutated genes (flagged in Suppl File S2) and were 
excluded from this analysis.
Moreover, mutated genes were catalogued according 
to a selection of eight pathways chosen on the basis of 
the existing knowledge about MM and lymphoid tumor 
malignancies [23, 24]. KEGG database (http://www 
.genome.jp/kegg/) was used to retrieve full lists of genes 
composing each pathway (Supplementary Methods).
Gene expression profiles of mutated genes
A panel of highly purified bone marrow PCs from 
55 MM and 21 pPCL patients (12 of whom investigated 
in this study) and from four healthy donors were 
previously profiled by us on GeneChip Human Gene 
1.0 ST array (Affymetrix, Santa Clara, CA, USA) [12]. 
These data were used to investigate gene expression 
levels of mutated genes and to perform hierarchical 
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clustering and differential expression analysis 
(Supplementary Methods). To assess the clustering 
abilities of mutated genes, the biological homogeneity 
index (BHI) [54] provided in R package clValid was 
used (Supplementary Methods).
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